Urispas: Targeted Relief for Bladder Spasms and Urinary Discomfort
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.60 | $48.09 (0%) | 🛒 Add to cart |
| 60 | $1.30 | $96.17 $78.14 (19%) | 🛒 Add to cart |
| 90 | $1.21 | $144.26 $109.19 (24%) | 🛒 Add to cart |
| 120 | $1.16 | $192.34 $139.25 (28%) | 🛒 Add to cart |
| 180 | $1.12 | $288.51 $201.36 (30%) | 🛒 Add to cart |
| 270 | $1.09 | $432.77 $294.52 (32%) | 🛒 Add to cart |
| 360 | $1.07
Best per pill | $577.03 $385.69 (33%) | 🛒 Add to cart |
Synonyms | |||
Urispas (generic name: flavoxate hydrochloride) is an antispasmodic medication specifically formulated to relieve symptoms associated with various urinary tract conditions. It works by relaxing the smooth muscle of the urinary bladder, thereby reducing frequent, urgent, or painful urination. This medication is prescribed to manage discomfort caused by cystitis, prostatitis, urethritis, and other related diagnoses, offering patients a reprieve from disruptive urinary symptoms and improving quality of life.
Features
- Active ingredient: Flavoxate hydrochloride 100 mg
- Anticholinergic and direct smooth muscle relaxant properties
- Tablet form for oral administration
- Typically prescribed as short-to-medium term therapy
- Manufactured under strict pharmaceutical quality standards
Benefits
- Reduces bladder muscle spasms, alleviating pain and urgency
- Decreases frequency of urination, allowing for longer periods between bathroom visits
- Improves control over urinary function, reducing incontinence episodes
- Helps restore comfort during urination, minimizing burning or discomfort
- Supports daily activities and sleep by reducing nighttime urination
- Enhances overall quality of life for individuals with chronic urinary conditions
Common use
Urispas is commonly prescribed for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence as may occur in cystitis, urethritis, prostatitis, and other lower urinary tract conditions. It is particularly useful in cases where inflammation or irritation leads to bladder muscle hyperactivity. Patients with overactive bladder (OAB) symptoms or those recovering from urological procedures may also benefit from this medication. It is important to note that Urispas treats the symptoms of these conditions but does not cure the underlying infection or pathology.
Dosage and direction
The usual adult dosage is one or two 100 mg tablets three or four times daily. The exact dosage should be determined by a healthcare provider based on the patient’s condition and response to therapy. Tablets should be swallowed whole with a full glass of water, with or without food. If gastrointestinal upset occurs, taking with food may help. Dosage adjustments may be necessary for elderly patients or those with hepatic impairment. Treatment duration is typically short-term; patients should not exceed the prescribed dosage or extend therapy without medical consultation.
Precautions
Before taking Urispas, inform your healthcare provider if you have glaucoma, gastrointestinal obstruction, urinary retention, or hepatic impairment. Use with caution in patients with tachycardia or cardiac arrhythmias. This medication may cause drowsiness or blurred vision; avoid driving or operating machinery until you know how it affects you. Elderly patients may be more sensitive to the effects of Urispas. Pregnant women should use only if clearly needed, and breastfeeding mothers should consult their doctor before use, as it is unknown if flavoxate passes into breast milk.
Contraindications
Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It should not be used in patients with gastrointestinal obstruction, paralytic ileus, intestinal atony, severe ulcerative colitis, or toxic megacolon. Contraindications also include untreated angle-closure glaucoma, myasthenia gravis, and obstructive uropathy. Patients with unstable cardiovascular status in acute hemorrhage or those with tachycardia should avoid this medication.
Possible side effect
Common side effects may include dry mouth, drowsiness, blurred vision, constipation, nausea, vomiting, and nervousness. Less frequently, patients may experience headache, dizziness, confusion (especially in elderly patients), tachycardia, palpitations, increased intraocular pressure, urinary retention, rash, or eosinophilia. These effects are often dose-related and may diminish with continued use. If any side effects persist or worsen, patients should contact their healthcare provider promptly. Serious allergic reactions are rare but may include rash, itching, swelling, severe dizziness, or trouble breathing.
Drug interaction
Urispas may interact with other anticholinergic drugs, potentially increasing side effects such as dry mouth, constipation, and blurred vision. Concurrent use with CNS depressants (alcohol, sedatives, tranquilizers) may enhance drowsiness and dizziness. It may antagonize the effects of metoclopramide and other prokinetic agents. Use with caution with MAO inhibitors, tricyclic antidepressants, or antipsychotics due to potential additive anticholinergic effects. Always inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.
Missed dose
If you miss a dose of Urispas, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up. Consistent dosing helps maintain stable symptom control, but occasional missed doses are unlikely to cause significant problems. If you frequently forget doses, consider setting reminders or discussing adherence strategies with your healthcare provider.
Overdose
Symptoms of overdose may include severe drowsiness, dizziness, dry mouth, blurred vision, flushing, fever, difficulty breathing, seizures, or loss of consciousness. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is typically supportive and symptomatic; activated charcoal may be administered if ingestion was recent. There is no specific antidote for flavoxate overdose. Provide medical personnel with information about the amount ingested and the time of consumption.
Storage
Store Urispas tablets at room temperature (15-30°C or 59-86°F) in their original container, away from light, moisture, and heat. Keep out of reach of children and pets. Do not store in bathrooms or near kitchen sinks where moisture levels are high. Properly discard any expired or unused medication according to local guidelines; do not flush down toilets or pour into drains unless instructed to do so.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication. The content provided here is not exhaustive; refer to the official prescribing information for complete details. Individual responses to medication may vary, and proper diagnosis and supervision are essential for safe and effective treatment.
Reviews
Clinical studies and patient reports indicate that Urispas effectively reduces urinary urgency, frequency, and discomfort in appropriately selected patients. Many users report significant improvement in symptoms within the first few days of treatment. Some patients note dry mouth or drowsiness as manageable side effects. Healthcare providers generally consider it a valuable option for symptomatic relief in various urological conditions, particularly when other treatments are unsuitable or insufficient. Long-term satisfaction often depends on proper patient selection and adherence to prescribed dosing guidelines.